Roche's Tecentriq Combination Therapy Demonstrates 50% Reduction in Risk of Recurrence in Phase 3 Trial for Stage 3 dMMR Colorectal Cancer, Establishing a New Standard of Care
Key Results from the Phase 3 Trial of the Atezolizumab Combination Therapy
In the ATOMIC Phase 3 trial, led by the National Cancer Institute (NCI), Roche's immunotherapy Tecentriq (atezolizumab) in combination with standard mFOLFOX6 chemotherapy showed promising results. This trial involved patients with stage 3 dMMR colorectal cancer who had undergone surgery. The combination therapy reduced the risk of disease recurrence and death by 50% compared to chemotherapy alone. The 3-year disease-free survival (DFS) rate was 86.3% in the combination group and 76.2% in the chemotherapy-alone group, demonstrating a hazard ratio (HR) of 0.50, which indicates a statistically significant improvement. This is the first Phase 3 data to demonstrate that adding immunotherapy to adjuvant therapy improves survival rates, making it a significant advancement in the field.
Synergistic Mechanism of Immune Checkpoint Inhibitors and Chemotherapy
mFOLFOX6, the foundation of the combination therapy, is a chemotherapy regimen that inhibits DNA replication and induces cell death in cancer cells. Atezolizumab, a monoclonal antibody that targets the PD-L1 protein, is added to block the immune evasion of cancer cells and enhance the activity of T cells. dMMR tumors have a high degree of genetic mutation, which maximizes their immunogenicity. The combination therapy simultaneously stimulates the death of cancer cells and the reconstruction of the body's immune defense system, which is the key to its clinical efficacy.
Paradigm Shift in the Global Colorectal Cancer Treatment Market
The global colorectal cancer treatment market is expected to exceed $15.4 billion by 2026, with precision medicine driving growth. While Merck's Keytruda has dominated the market for first-line treatment of metastatic dMMR colorectal cancer, this study allows Roche to gain a foothold in the previously unexplored market of early adjuvant therapy for stage 3 cancer. This is expected to provide a significant commercial breakthrough for Tecentriq, which recorded sales of approximately 3.64 billion Swiss francs (CHF, approximately $4.1 billion) in 2024, by expanding its indications.
Regulatory Approval Prospects and Impact on Healthcare
Based on the results presented at the 2025 American Society of Clinical Oncology (ASCO) Plenary Session (LBA1), Roche plans to apply for accelerated approval from the FDA and other global regulatory agencies. If approved, dMMR gene testing will become a standard companion diagnostic biomarker, which will also have a positive impact on the diagnostics industry. Furthermore, by improving the cure rate for stage 3 colorectal cancer, which has a high recurrence rate, this therapy can contribute to improved public health and long-term reductions in social healthcare costs.
This Phase 3 trial (ATOMIC) has established a groundbreaking milestone in the treatment of stage 3 dMMR colorectal cancer in the adjuvant setting. The impressive hazard ratio (HR) of 0.50 strongly supports the potential for first-in-class status, and upon FDA approval, it is expected to lead to a significant increase in Roche's market share in the $15.4 billion global colorectal cancer treatment market. By securing a strong, exclusive competitive advantage in the early colorectal cancer space, Roche is poised to challenge Merck's Keytruda, which has been the leader in the metastatic dMMR colorectal cancer market. This is a key factor that will directly impact the company's long-term valuation. Furthermore, the success of early immune checkpoint therapy is expected to drive the development of other solid tumor adjuvant therapy pipelines, creating a ripple effect in R&D.
Source: ClinicalTrials.gov (api_ct)